• Batdelger D, Dandii D, Dahgwahdorj Ya, Erdenetsogt E, Oyunbileg J, Tsend N, Bayarmagnai B, Jirathitikal V, Bourinbaiar AS. Clinical experience with therapeutic vaccines designed for patients with hepatitis. Curr Pharm Design 2009;15:1159-1171.

  • Bourinbaiar AS, Jirathitikal V. Safety and efficacy trial of adipose-tissue derived oral preparation V-6 Immunitor (V-6): results of open-label, two-month, follow-up study. Lipids Health Dis 2010;9:14.

  • Bourinbaiar AS, Jirathitikal V. Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices. Vaccine 2010;28:2763-8.

  • Bourinbaiar AS, Orlovsky V, Jirathitikal V. Preliminary evidence of safety and efficacy of an orally administered, heat-inactivated H5N1 influenza vaccine.  Proc Vaccinol 2010;2:60-65. doi:10.1016/j.provac.2010.03.011

  • Arjanova OV, Prihoda ND, Yurchenko LV, Sokolenko NI, Frolov VM, Tarakanovskaya MG, Jirathitikal V, Bourinbaiar AS. Phase 2 trial of V-5 Immunitor (V5) in patients with chronic hepatitis C co-infected with HIV and Mycobacterium tuberculosis. J Vaccines Vaccination 2010;1:103